Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CT-0525 |
Synonyms | |
Therapy Description |
CT-0525 are monocytes engineered to express a chimeric antigen receptor (CAR) targeting ERBB2 (HER2), which potentially inhibit tumor growth (Journal for ImmunoTherapy of Cancer 2022;10, Suppl_2). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CT-0525 | CT0525|CT 0525 | HER2 (ERBB2) Immune Cell Therapy 6 | CT-0525 are monocytes engineered to express a chimeric antigen receptor (CAR) targeting ERBB2 (HER2), which potentially inhibit tumor growth (Journal for ImmunoTherapy of Cancer 2022;10, Suppl_2). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06254807 | Phase I | CT-0525 | CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors | Recruiting | USA | 0 |